Increased plasma oligomeric alpha-synuclein in patients with lysosomal storage diseases
Neuroscience Letters; doi:10.1016/j.neulet.2014.09.041.
Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson’s disease
Acta Neurolpathol.; doi: 10.1007/s00401-014-1314-y.
Quantitative Measurement of Intact Alpha-Synuclein Proteoforms from Post-Mortem Control and Parkinson's Disease Brain Tissue by Intact Protein Mass Spectrometry
Scientific Reports; doi:10.1038/srep05797
The use of nanopore analysis for discovering drugs which bind to α-synuclein for treatment of Parkinson's disease
European Journal of Medicinal Chemistry; DOI: 10.1016/j.ejmech.2014.07.090.
Multifunctional D2/D3 Agonist D-520 with High in Vivo Efficacy: Modulator of Toxicity of Alpha-Synuclein Aggregates
ACS Chemical Neuroscience; DOI: 10.1021/cn500084x.
Aldehyde dehydrogenase 1 defines and protects a nigrostriatal dopaminergic neuron subpopulation
JCI: The Journal of Clinical Investigation; doi:10.1172/JCI72176..
Cu(II) and dopamine bind to α-Synuclein and cause large conformational changes
FEBS Journal; DOI: 10.1111/febs.12817
Extracellular α-Synuclein Leads to Microtubule Destabilization via GSK-3β-Dependent Tau Phosphorylation in PC12 Cells.
PLOS One; DOI: 10.1371/journal.pone.0094259.
Resistance of naturally secreted α-synuclein to proteolysis
FASEB Journal; doi: 10.1096/fj.13-245852.
Comparable Autoantibody Serum Levels against Amyloid- and Inflammation-Associated Proteins in Parkinson’s Disease Patients and Controls
PLoS ONE; DOI: 10.1371/journal.pone.0088604.